Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Long-Term Results Support De-escalated Neoadjuvant Therapy in HER2-Positive Breast Cancer

07/22/2026

Paolo Tarantino, MD, PhD

Paolo Tarantino, MD, PhD, discusses 5-year results from the phase 2 DAPHNe trial showing that neoadjuvant paclitaxel, trastuzumab, and pertuzumab achieved excellent long-term outcomes with no distant recurrences among patients with...

Paolo Tarantino, MD, PhD,...

07/22/2026

Oncology

Videos

Vepdegestrant Improves Outcomes in ESR1-Mutant ER-Positive Metastatic Breast Cancer

06/29/2026

Komal Jhaveri, MD

Komal Jhaveri, MD, discusses results from the phase 3 VERITAC-2 trial which demonstrated that vepdegestrant improved progression-free survival in patients with ESR1-mutant ER-positive, HER2-negative metastatic breast cancer, supporting its...

Komal Jhaveri, MD, discusses...

06/29/2026

Oncology

Videos

Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations

06/26/2026

Erika Hamilton, MD

Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...

Erika Hamilton, MD, discusses...

06/26/2026

Oncology

Videos

Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction

06/24/2026

Walter Weber, MD

Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...

Walter Weber, MD, discusses...

06/24/2026

Oncology

Videos

Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer

06/24/2026

Peter Schmid, MD, PhD

Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...

Peter Schmid, MD, PhD, discusses...

06/24/2026

Oncology

Videos

Frontline Sacituzumab Govitecan Continues to Show Benefit in PD-L1–Positive Triple-Negative Breast Cancer

06/24/2026

Kevin Kalinsky, MD, MS

Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...

Kevin Kalinsky, MD, discusses...

06/24/2026

Oncology

Videos

Pembrolizumab Demonstrates Long-Term Survival Benefit in in Early-Stage Triple-Negative Breast Cancer

06/24/2026

Peter Schmid, MD, PhD

Peter Schmid, MD, PhD, discusses final results from the KEYNOTE-522 study showing durable event-free and overall survival benefits with pembrolizumab plus chemotherapy in patients with stage 2/3 triple-negative breast cancer, confirming its...

Peter Schmid, MD, PhD, discusses...

06/24/2026

Oncology

Videos

Prosigna-Guided Treatment Safely Reduces Chemotherapy Use in HR-Positive, HER2-Negative Early Breast Cancer

06/19/2026

Robert Stein, PhD

Robert Stein, PhD, discusses results from the phase 3 OPTIMA trial showing that Prosigna-guided treatment identified approximately 68% of patients with HR-positive, HER2-negative early breast cancer who could safely avoid chemotherapy without...

Robert Stein, PhD, discusses...

06/19/2026

Oncology

Videos

Sacituzumab Govitecan Plus Pembrolizumab Delivers Benefit Independent of TROP2 Expression in Triple-Negative Breast Cancer

06/19/2026

Sara Tolaney, MD

Sara Tolaney, MD, discusses biomarker analysis results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab improved progression-free survival regardless of TROP2 expression, BRCA mutation status, or HER2 expression...

Sara Tolaney, MD, discusses...

06/19/2026

Oncology

Videos

SENOMAC Trial Confirms Axillary Surgery Can Be Safely Omitted in Node-Positive Breast Cancer

06/18/2026

Jana de Boniface, MD, PhD

Jana de Boniface, MD, PhD, discusses final results from the phase 3 SENOMAC trial results showing that omission of completion axillary lymph node dissection in patients with breast cancer and 1 to 2 sentinel lymph node macrometastases...

Jana de Boniface, MD, PhD,...

06/18/2026

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Inotuzumab Ozogamicin Demonstrates High Response Rates in Pediatric Patients With Very High-Risk First Relapse B-Cell Acute Lymphoblastic Leukemia

07/24/2026

Emily Estrada

Results from cohort 3 of the phase 1/2 ITCC-059 trial demonstrated that inotuzumab ozogamicin produced high response rates with a manageable safety profile in pediatric patients with very high-risk first relapse of B-cell acute lymphoblastic...

Results from cohort 3 of the...

07/24/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

07/23/2026

Stephanie Holland

The FDA accepted for review a New Drug Application for daraxonrasib in adults with previously treated metastatic pancreatic ductal adenocarcinoma based on the phase 3 RASolute 302 trial, which demonstrated improvements in overall survival,...

The FDA accepted for review a...

07/23/2026

Oncology

News

Phase 3 MonumenTAL-6 Trial Demonstrates Significant Survival Benefit With Dual-Bispecific Immunotherapy in Relapsed or Refractory Multiple Myeloma

07/23/2026

Stephanie Holland

Results from the phase 3 MonumenTAL-6 trial demonstrated that teclistamab plus talquetamab significantly improved progression-free and overall survival compared with standard therapy in patients with relapsed or refractory multiple myeloma,...

Results from the phase 3...

07/23/2026

Oncology

News

Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk Myelodysplastic Syndromes

07/22/2026

Stephanie Holland

The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...

The phase 3 ENHANCE trial...

07/22/2026

Oncology

News

Consolidative Thoracic Radiotherapy Increases Toxicity Without Survival Benefit in Extensive-Stage Small Cell Lung Cancer

07/22/2026

Stephanie Holland

Results from the phase 2 TREASURE trial demonstrated that adding consolidative thoracic radiotherapy to atezolizumab maintenance increased toxicity without improving survival in patients with extensive-stage small cell lung cancer, arguing...

Results from the phase 2...

07/22/2026

Oncology

FDA Approval

FDA Approves Zidesamtinib for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer

07/22/2026

Stephanie Holland

The FDA approved zidesamtinib for adults with previously treated locally advanced or metastatic ROS1-positive non-small cell lung cancer based on findings from the phase 1/2 ARROS-1 trial demonstrating durable responses, including in patients...

The FDA approved zidesamtinib...

07/22/2026

Oncology

News

Alpha DaRT® Plus Pembrolizumab Achieves 100% Response Rate in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

07/21/2026

Stephanie Holland

Results from a prospective study demonstrated that Alpha DaRT® combined with pembrolizumab achieved a 100% systemic objective response rate among evaluable patients with recurrent unresectable or metastatic head and neck squamous cell...

Results from a prospective study...

07/21/2026

Oncology

News

Safusidenib Demonstrates Durable Responses and Prolonged Disease Control in Grade 2 IDH1-Mutant Glioma

07/21/2026

Emily Estrada

Updated findings from the phase 2 J201 trial demonstrated that safusidenib, a selective mutant IDH1 inhibitor, produced durable responses and prolonged disease control in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant...

Updated findings from the phase...

07/21/2026

Oncology

News

Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma

07/16/2026

Stephanie Holland

Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...

Results from the phase 3...

07/16/2026

Oncology

News

Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer

07/16/2026

Stephanie Holland

Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...

Interim results from the...

07/16/2026

Oncology